The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.
Header
News Archive
Showing 50 results
October 2021
-
Media Release
Novartis applauds Quebec, the first province to list Zolgensma® for the treatment of pediatric patients with spinal muscular atrophy (SMA)
Public reimbursement is effective October 20th and will apply for children with SMA following the recommendation from the Institut national d'excellence en santé et services sociaux Zolgensma is… -
Media Release
New campaign highlights urgent need for action to address the growing crisis of preventable vision loss and blindness
This World Sight Day, Fighting Blindness Canada and the Canadian Council of the Blind have partnered with Novartis Canada to launch “All Eyes on You”, a campaign urging Canadians to lend their… -
Media Release
Novartis and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for Zolgensma® for the treatment of pediatric patients with spinal muscular atrophy (SMA)
Dorval, Quebec, October 13, 2021 — Novartis Pharmaceuticals Canada Inc. today announced that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent… -
Media Release
Novartis Pharmaceuticals Canada Inc. announces digital innovation partnership in multiple sclerosis with Innodem Neurosciences
Clinical trial will study new technology that tracks eye movement to assist diagnosis and monitor disease progression Dorval, Quebec, October 5, 2021 — Novartis Pharmaceuticals Canada Inc. (…
April 2021
-
Media Release
Ilaris® receives Health Canada approval as first of its kind treatment for rare, inflammatory disorder, adult-onset Still’s disease
The approval of Ilaris (canakinumab) in the treatment of adult-onset Still’s disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening… -
Media Release
Alberta sites join network of certified centres to deliver CAR-T therapy, Kymriah® (tisagenlecleucel)i
Expansion of treatment centre network includes two specialized centres in Alberta certified to deliver Kymriah to Canadian patients with relapsed/refractory (r/r) pediatric and young adult B-cell… -
Media Release
Novartis in Canada named a Top 50 Best Workplace™ in the country
Open feedback by Novartis associates contributed to coveted Canadian employer recognition Novartis ranked among the companies with the highest levels of trust and most inclusive cultures in the…
March 2021
-
Media Release
Health Canada approves Kesimpta®, the first and only self-administered targeted B-cell therapy for relapsing remitting multiple sclerosis (RRMS)
Kesimpta® (ofatumumab) delivers superior efficacy with a favourable safety profile and can be self-administered at home, addressing a significant unmet need for people living with relapsing… -
Media Release
Novartis’ KISQALI® (ribociclib) product monograph in Canada now includes MONALEESA-3 data demonstrating statistically significant improvement in overall survival in postmenopausal women with HR+/HER2- advanced breast cancer
KISQALI® is currently the only CDK4/6 inhibitor that has demonstrated statistically significant improvement in overall survival (key secondary endpoint) with various endocrine treatment partners…
